Twitter Activities

Breast Cancer

HER2 Breast Cancer Tweetorials

ASCP is hosting a CME/CMLE-accredited Tweetorial series designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the latest evidence regarding HER2-low breast cancer and HER2 testing guidelines. Each Tweetorial offers 0.5 CME/CMLE credits.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. Provided by the American Society for Clinical Pathology in partnership with Q Synthesis.

Tweetorial 1

HER2-low Emerges as a New Classification

This Tweetorial addresses updates from the latest clinical studies on HER2-low breast cancer, HER2-low definition and classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.
View Now
Tweetorial 2

Examining the Implications of HER2-low

This Tweetorial covers HER2-low breast cancer, HER2-low classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

View Now
Tweetorial 3

HER2 Intratumoral Heterogeneity

This Tweetorial will cover the following topics: HER2-low breast cancer, HER2-low classification, and HER2 intratumoral heterogeneity.

View Now
Tweetorial 4

HER2 Equivocal and HER2-low

This Tweetorial covers HER2-low breast cancer, HER2-low classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

View Now
Tweetorial 5

Disparities in Care and Updates in HER2-low

This Tweetorial will cover the following topics: disparities in breast cancer care and updates in HER2-low breast cancer.

View Now
Tweetorial 6

Optimizing Communication When HER2 Expression Is Low

This Tweetorial covers the following topic: ways to optimize communication when HER2 expression levels are low.

View Now